Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone.

Abstract:

:Recent meta-analytic work suggests atypical antipsychotics may be clinically superior to conventional antipsychotics, although many stable patients remain on conventional antipsychotic treatment. A long-acting atypical agent may benefit patients in realms of both advanced medication delivery and mechanism of action. In a multicentre, open-label study of 725 patients with schizophrenia or schizoaffective disorder, patients received 25-75 mg of long-acting risperidone every 2 weeks for up to 50 weeks, with performance of standard safety and efficacy assessments. Data are presented on stable patients receiving oral conventional antipsychotics at study entry. In the 46 (6.3%) stable patients receiving oral conventional antipsychotics (followed between 6 months and 1 year; mean 468 days), mean (SD) Positive and Negative Syndrome Scale (PANSS) total score improved from 73.1+/-17.2 to 64.5+/-18.2 (P=0.0006). Clinical improvement of > or =20%, > or =40% or > or =60% reduction in PANSS total score occurred in 49%, 29% and 10% of stable patients, respectively. Extrapyramidal Symptom Rating Scale subjective ratings and objective physician ratings (parkinsonism) decreased significantly (P<0.05). The hypothesis that switching stable patients treated with oral conventional antipsychotics to long-acting risperidone may result in significant improvements in psychiatric and movement disorder symptomatology merits further investigation.

authors

van Os J,Bossie CA,Lasser RA

doi

10.1097/01.yic.0000122861.35081.16

subject

Has Abstract

pub_date

2004-07-01 00:00:00

pages

229-32

issue

4

eissn

0268-1315

issn

1473-5857

pii

00004850-200407000-00006

journal_volume

19

pub_type

临床试验,杂志文章,多中心研究
  • Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.

    abstract::The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199705000-00004

    authors: Sommers DK,Snyman JR,van Wyk M,Blom MW,Huang ML,Levron JC

    更新日期:1997-05-01 00:00:00

  • Elective combined electroconvulsive and clozapine therapy.

    abstract::Clozapine therapy does not produce the rapid response that may be required in severely disturbed patients. The latter, not uncommonly, obstruct treatment by refusing to give blood for haematological monitoring or refusing to swallow tablets. Whereas electroconvulsive therapy (ECT) may be used for rapid behavioural con...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199903000-00002

    authors: James DV,Gray NS

    更新日期:1999-03-01 00:00:00

  • Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

    abstract::Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.yic.0000215083.57801.11

    authors: Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

    更新日期:2006-11-01 00:00:00

  • Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome.

    abstract::Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

    更新日期:1999-01-01 00:00:00

  • Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.

    abstract::One hundred and sixty patients with a primary diagnosis of obsessive-compulsive disorder were enrolled in a multicentre, randomized, double-blind, placebo-controlled study of fluvoxamine. After a placebo washout phase, patients were randomized to treatment with placebo or fluvoxamine (100-300 mg/day) for 10 weeks. Sev...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Goodman WK,Kozak MJ,Liebowitz M,White KL

    更新日期:1996-03-01 00:00:00

  • Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

    abstract::Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000016

    authors: Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

    更新日期:2014-03-01 00:00:00

  • Efficacy of risperidone in treating the hyperactive symptoms of delirium.

    abstract::Forty-one delirious patients who received risperidone treatment and 36 who received haloperidol treatment were retrospectively analysed. Ten-point visual analog scales (scored 0 for none to 10 for extremely severe) for hyperactive and hypoactive syndromes of delirium were used for efficacy evaluation. Psychiatrists sc...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200405000-00008

    authors: Liu CY,Juang YY,Liang HY,Lin NC,Yeh EK

    更新日期:2004-05-01 00:00:00

  • Current aspects of valproate in bipolar disorder.

    abstract::For more than 30 years, lithium has been the drug of choice for the treatment of bipolar disorder. However, it has numerous adverse effects, a relatively slow onset of action, many common drug-drug interactions, and a narrow therapeutic index. Because of these problems, researchers looked for alternative and/or adjunc...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200015010-00001

    authors: Lennkh C,Simhandl C

    更新日期:2000-01-01 00:00:00

  • Application of an individually predicted dosage of amitriptyline to the treatment of depression.

    abstract::The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198710000-00003

    authors: Roy D,Dawling S

    更新日期:1987-10-01 00:00:00

  • Gender and age differences in the growth hormone response to pyridostigmine.

    abstract::Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199100620-00005

    authors: Lucey JV,O'Keane V,O'Flynn K,Clare AW,Dinan TG

    更新日期:1991-07-01 00:00:00

  • Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder.

    abstract::Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199809000-00008

    authors: Hamner MB,Frueh BC

    更新日期:1998-09-01 00:00:00

  • Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.

    abstract::The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000094

    authors: Clayton AH,Hwang E,Kornstein SG,Tourian KA,Cheng RF,Abraham L,Mele L,Boucher M

    更新日期:2015-11-01 00:00:00

  • Pharmacotherapy of bulimia nervosa--experience with fluoxetine.

    abstract::A number of compounds having an effect on serotonergic transmission have been shown to have a beneficial therapeutic action in patients with bulimia nervosa. Many previous studies, however, have suffered from methodological shortcomings, in particular small population sizes. This article reviews present data which sug...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1097/00004850-199300840-00014

    authors: Wood A

    更新日期:1993-01-01 00:00:00

  • Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.

    abstract::Two selective serotonin reuptake inhibitors (SSRIs), citalopram and fluoxetine, both at a daily dose of 20 mg, were compared in patients with unipolar major depression treated in general practice. This was a multicentre, double-blind, randomized trial carried out in France. The duration of treatment was 8 weeks. Patie...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Patris M,Bouchard JM,Bougerol T,Charbonnier JF,Chevalier JF,Clerc G,Cyran C,Van Amerongen P,Lemming O,Høpfner Petersen HE

    更新日期:1996-06-01 00:00:00

  • Serotonin: current understanding and the way forward.

    abstract::Serotonin is a key neurotransmitter in the central nervous system. In recent years its role in the pathophysiology and pharmacology of depression has been extensively investigated. Neuroendocrine studies suggest decreased serotonergic responsivity in patients with major depression. The fact that the majority of patien...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Dinan TG

    更新日期:1996-03-01 00:00:00

  • The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

    abstract::Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000009

    authors: Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

    更新日期:2014-01-01 00:00:00

  • Is amisulpride an 'atypical' atypical antipsychotic agent?

    abstract::Amisulpride is a novel antipsychotic with a pharmacological and clinical profile that differs from that of other atypical agents. Amisulpride is highly selective for dopamine D2/D3 receptor subtypes located in the limbic region, which is highly predictive of potent antipsychotic activity with a low potential to cause ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Lecrubier Y

    更新日期:2000-12-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • Comorbidities in social phobia.

    abstract::In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199710006-00004

    authors: Lecrubier Y,Weiller E

    更新日期:1997-10-01 00:00:00

  • Patient-based and clinician-based support for the remission criteria in schizophrenia.

    abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000224791.06159.88

    authors: Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

    更新日期:2007-01-01 00:00:00

  • Refining treatment approaches in obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199612005-00003

    authors: Fineberg N

    更新日期:1996-12-01 00:00:00

  • Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study.

    abstract::This study evaluated the efficacy of pregabalin augmentation of antidepressant treatment in patients with posttraumatic stress disorder (PTSD). Nine patients meeting Diagnostic and Statistical Manual, fourth edition criteria for PTSD who were on stable doses of antidepressants were treated open label with flexibly dos...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32831feea9

    authors: Pae CU,Marks DM,Han C,Masand PS,Patkar AA

    更新日期:2009-01-01 00:00:00

  • Brotizolam: a new short-acting hypnotic.

    abstract::A new short-acting thieno-diazepine compound, brotizolam, has been compared to nitrazepam in a double-blind trial. Following an initial 3-day control period with no treatment, insomniac patients were allocated to 2 weeks treatment with one or the other drug according to random selection. This was then followed by a fu...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198601000-00005

    authors: Wheatley D

    更新日期:1986-01-01 00:00:00

  • Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.

    abstract::Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e328340c0de

    authors: Ventriglio A,Vincenti A,Centorrino F,Talamo A,Fitzmaurice G,Baldessarini RJ

    更新日期:2011-03-01 00:00:00

  • New aspects in the treatment of depression.

    abstract::Because of the limitations in efficacy and safety of the older tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) a number of new approaches have been made in recent years to the treatment of depression to obtain more effective, more rapidly acting, better tolerated and safer drugs. One tactic has...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199206005-00004

    authors: Silverstone T

    更新日期:1992-06-01 00:00:00

  • Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.

    abstract::Most antidepressants in clinical use are believed to function by enhancing neurotransmission of serotonin [5-hydroxytryptamine (5-HT)] and/or norepinephrine (NE) via inhibition of neurotransmitter reuptake. Agents that affect reuptake of both 5-HT and NE (serotonin-norepinephrine reuptake inhibitors) have been postula...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/YIC.0b013e3282f41d7e

    authors: Trivedi MH,Desaiah D,Ossanna MJ,Pritchett YL,Brannan SK,Detke MJ

    更新日期:2008-05-01 00:00:00

  • The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series.

    abstract::Musical hallucinations (MHs), characterized by the hearing of tunes, melodies, or songs, is a relatively under-recognized phenomenon among elderly individuals with hearing impairment. In some patients, MHs represent a complex psychopathological phenomenon, hallucinatory in content and obsessive-compulsive (OC) in form...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000037

    authors: Bergman J,Pashinian A,Weizman A,Poyurovsky M

    更新日期:2014-09-01 00:00:00

  • Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.

    abstract::It has been suggested that the atypical antipsychotic drugs may induce a rapid improvement in individuals with melancholic depression. This might reflect a specific or non-specific effect on mood and other parameters. To examine this issue, ten consecutive patients, for whom olanzapine augmentation was judged a clinic...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200203000-00008

    authors: Parker G

    更新日期:2002-03-01 00:00:00

  • Agitation in the demented elderly: a role for benzodiazepines?

    abstract::"Agitation" is a term that is used to describe a wide range of dysfunctional behaviours in geriatric populations. The term is so widely used that in many cases it loses clinical meaning and therefore a more restricted use of the term is suggested. When patients with agitation are identified it is important to look for...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199100630-00002

    authors: Ancill RJ,Carlyle WW,Liang RA,Holliday SG

    更新日期:1991-01-01 00:00:00

  • Striking a balance between safety and efficacy: experience with the SSRI sertraline.

    abstract::Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacother...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Casey DE

    更新日期:1994-06-01 00:00:00